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Abstract: The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors within 
the renin–angiotensin system, which mediate tissue-protective actions such as anti-inflammation, 
antifibrosis, and antiapoptosis. In recent years, several programs have been launched in order 
to develop drugs that act as agonists on the AT2R or MAS to take therapeutic advantage of 
the protective and regenerative properties of these receptors. This review article will focus on 
recent data obtained in preclinical animal and in vitro models with new AT2R-agonistic mole-
cules (Compound 21 and β-amino acid substituted angiotensin II) and with relevance for blood 
pressure (BP) regulation or hypertensive end-organ damage. These data will include studies on 
vasodilation/vasoconstriction in isolated resistance arteries ex vivo, studies on kidney function, 
studies on vascular remodeling, and studies that measured the net effect of AT2R stimula-
tion on BP in vivo. Current data indicate that although AT2R stimulation causes vasodilation 
ex vivo and promotes natriuresis, it does not alter BP levels in vivo acutely – at least as long 
as there is no additional low-dose blockade of AT1R. However, AT2R stimulation alone is able 
to attenuate hypertension-induced vascular remodeling and reduce arterial stiffening, which in 
more chronic settings and together with the natriuretic effect may result in modest lowering 
of BP. We conclude from these preclinical data that AT2R agonists are not suitable for antihy-
pertensive monotherapy, but that this new future drug class may be beneficial in combination 
with established antihypertensives for the treatment of hypertension with improved protection 
from end-organ damage.
Keywords: renin–angiotensin system, AT2-receptor, vasodilation, blood pressure, kidney 
function, vascular remodeling
Introduction
The renin–angiotensin system (RAS) is essentially involved in the control of blood 
pressure (BP) and body volume.1 Angiotensin II (Ang II), acting via the angiotensin 
type 1 receptor (AT1R), causes vasoconstriction as well as sodium and water retention.2 
Furthermore, it is involved in the pathogenesis of hypertensive and diabetic end-organ 
damage by promoting inflammation and fibrosis. Pharmacological interference with 
the RAS by direct renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, 
or AT1R blockers (ARB) is a common therapeutic approach for the treatment of 
hypertension.3 In addition, ACE inhibitors and ARBs are standard treatment for heart 
failure and diabetic nephropathy.
In the recent past, research on potential new drug targets within the RAS and the 
development of respective novel drugs have gained significant momentum.4–6 These 
current efforts mainly aim at making therapeutic use of the so-called protective RAS, 
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which comprises the AT2R and the ACE2-angiotensin-(1-7) 
(Ang-[1-7])-MAS axis. Both the AT2R and the receptor MAS 
mediate a broad array of tissue-protective effects, including 
anti-inflammation, antifibrosis, antiapoptosis, neuropro-
tection, favorable metabolic effects, and  vasodilation. In 
particular, their ability to counteract vasoconstriction, inflam-
mation, and fibrosis makes the AT2R and MAS potential 
drug targets for the treatment of hypertension and related 
end-organ damage. Interestingly, there seems to be a positive 
feedback loop within the protective RAS because, as has been 
published very recently, the expression of ACE2, Ang-(1-7), 
and MAS, as well as ACE2 activity, were increased in the 
kidneys of obese Zucker rats treated for 2 weeks with the 
AT2R agonist CGP 42112A.7
Regarding the AT2R, there are currently three types 
of new agonistic molecules with the potential for drug 
 development: 1) the nonpeptide small molecule agonist 
Compound 21 (C21; Vicore Pharma, Gothenburg,  Sweden, 
www.vicorepharma.com),8 2) the cyclic Ang II deriva-
tive (one amino acid exchanged for another, unknown 
 [unpublished] amino acid) LP2-3 (Lanthio Pharma, 
Groningen, the Netherlands, www.lanthiopep.nl),9 and 3) 
a group of Ang II derivatives in which individual amino 
acids in the sequence of native Ang II are substituted by the 
respective β-amino acid.10 C21 is currently in the final stage 
of preclinical development and is expected to enter clinical 
testing in 2014, the status of LP2-3 is unknown, and the 
β-amino acid substituted molecules are currently used only 
for academic purposes.
This review article will discuss physiology and potential 
therapeutic use of the AT2R with a focus on its role in BP 
regulation and hypertensive end-organ damage.
Vasodilation and blood pressure
Stimulation of the AT2R has been shown to act in a vasodila-
tory way in various species and multiple vascular beds such as 
mesenteric,11–15 renal,16–18 coronary,19 cerebral,20 cutaneous,21 
and uterine arteries.22,23 In addition, AT2R knockout mice 
exhibit higher basal BP levels than wild-type mice, and they 
react with a stronger increase in BP to infusion of Ang II.24,25 
Conversely, in mice overexpressing AT2Rs in the vasculature, 
the pressor response to Ang II is markedly impaired.26
Vasodilation was also shown for more recently developed 
AT2R agonists such as the first nonpeptide agonist C218 or for 
the new peptide agonists generated by substituting individual 
amino acids in the sequence of native Ang II by the respective 
β-amino acid (Table 1).9 Vasodilation in response to these 
new ligands at concentrations between 10−11 and 10−6 M was 
observed in aorta from normotensive mice or hypertensive 
rats and in mouse mesenteric arteries in an AT2R-dependent 
manner, because these effects could be blocked by the AT2R 
antagonist PD 123319.10,27  Vasodilation in response to C21 was 
also reported by Verdonk et al28 in coronary, iliac, and mesen-
teric arteries of rats and mice; however, only at concentrations 
between 10−6 and 10−3 M. This vasodilatory response of C21 
was unrelated to the AT2R because it could not be blocked 
by the AT2R antagonist PD 123319, which with 1 µmol/L, 
however, was underdosed for most tested concentrations of 
C21, and because it was absent in AT2R-deficient mice. The 
mechanism of AT2R-unrelated vasodilation in response to 
C21 is still unknown but may involve blockade of calcium 
transport into the cell. Vasodilation caused by very high 
concentrations of C21 was preceded by a short vasoconstric-
tion, which was obviously due to AT1R stimulation, because 
it could be blocked by AT1R antagonists.28 This observation 
was not surprising, as Bosnyak et al27 had previously described 
that C21 stimulates the AT1R at very high concentrations, 
resulting in a rise in BP. In general, most small molecule 
drugs lose specificity at concentrations .1 µM or even 
lower. Well-known examples are β2-receptor mimetics used 
for the treatment of asthma, or β1-receptor blockers used 
for the treatment of hypertension, both of which bind to the 
respective other receptor subtype at high concentrations. For 
example, the Ki of the β2-receptor mimetic salmeterol, which 
possesses the highest selectivity of this drug class, is 24.6 nM 
for the β2-receptor and 1,600 nM for the β1-receptor; the 
 selective β1-receptor blocker metoprolol has a Ki of 47 nM for 
the β1-receptor and of 2.960 nM for the β2-receptor.29,30 With 
a Ki for the AT2R of 0.4 nM (2 nM for the human receptor) 
and .10,000 mM for the AT1R, the selectivity of C21 is not 
any worse than selectivity of so-called selective β-blockers 
or β2-receptor mimetics.
It seems logical that a hormone or drug that is able to cause 
vasodilation in isolated blood vessels would also be able to lower 
BP in animals and/or humans, as the vascular tone in resistance 
arteries is a major determinant of systolic BP. However, for the 
AT2R, this seems not to be the case (Table 2). Several studies 
using peptide or nonpeptide AT2R agonists, including the new 
molecules discussed previously, demonstrated that an AT2R-
mediated decrease in BP occurred only when there was a con-
comitant low-dose blockade of AT1Rs. For example, this was 
shown by the Carey et al31 in conscious, normotensive Sprague 
Dawley rats and by Barber et al32 in conscious, normotensive 
Wistar Kyoto and spontaneously hypertensive rats (SHR) in a 
PD 123319-reversible manner.10,27 The only exceptions were BP 
measurements in anesthetized rats, which were part of the first 
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description of design and synthesis of C21.8 In this study, C21 
caused a fall in BP of up to 25 mmHg. However, it has to be 
noted that anesthesia probably caused unphysiological effects 
of this pharmacological intervention with the RAS, which is 
activated by anesthesia.33
The observation that AT2R stimulation lowers BP only in 
the presence of low-level AT1R blockade indicates that in vivo a 
continuous angiotensinergic tone mediated via the AT1R seems 
dominant over any vasodilatory effect of AT2Rs. Consequently, 
AT2R agonists will most likely not become antihypertensive 
drugs suitable for monotherapy. However, due to their tissue-
protective effects discussed as follows, the combination of 
established antihypertensives with AT2R agonists may result 
in better long-term prevention of hypertensive end-organ dam-
age. Moreover, long-term therapy with AT2R agonists may 
have a modest BP-lowering effect due to structural changes of 
the vessel walls (see paragraph about “Vascular remodeling” 
below) and due to a recently described diuretic effect (see 
paragraph about “AT2 receptor activation in renal physiology 
and disease” below).34–36 AT2R stimulation may further act 
antihypertensive by CNS related mechanisms that become 
apparent only if C21, which crosses the blood–brain barrier 
only very poorly, is applied intracerebroventricularly.37
Normal pregnancy and preeclampsia are conditions 
 during which expression of components of the RAS is altered 
in a way that the peripheral and tissue RAS are activated.38 
In preeclampsia in patients or in respective animal models, 
the ratio of expression of AT1R and AT2R changes is favor 
of the AT1R in placental and uterine tissue and arteries.39–41 
The AT2R has been described to act in a vasodilatory man-
ner and to counteract the enhanced vasoconstrictive effect 
of Ang II via the AT1R during pregnancy.22 Thus, it can 
Table 1 effects of new AT2R agonists on vascular tone ex vivo
AT2 agonist Type of vessel Species Effective concentration Result Reference
β-substituted  
Ang peptides
Aorta Mouse 10−12 to 10−6 M vasodilation in presence of AT1R 
blocker
8
β-substituted  
Ang peptides
Aorta Mouse 10−12 to 10−6 M vasodilation in absence of AT1R 
blocker
8
C21 Aorta Mouse 10−10 to 10−6 M vasodilation in presence of AT1R 
blocker
14
C21 Aorta SHR 10−11 to 10−6 M vasodilation in presence of AT1R 
blocker
14
C21 Mesenteric artery Mouse 10−10 to 10−6 M vasodilation in presence of AT1R 
blocker
14
C21 Aorta Mouse 10−09 to 10−6 M vasodilation in absence of AT1R 
blocker
14
C21 Coronary  
microartery
Human 10−06 to 10−4 M vasodilation in absence of AT1R 
blocker
15
C21 Iliac artery wistar rat 10−07 to 10−4 M vasodilation in absence of AT1R 
blocker
15
C21 Mesenteric artery wistar rat 10−07 to 10−4 M vasodilation in absence of AT1R 
blocker
15
C21 Mesenteric artery SHR 10−08 to 10−4 M vasodilation in absence of AT1R 
blocker
15
C21 Iliac artery wistar rat 10−10 to 10−4 M No effect 15
C21 Iliac artery SHR 10−05 to 10−4 M vasoconstriction 15
C21 Iliac artery Mouse 10−07 to 10−4 M vasodilation in absence of AT1R 
blocker
15
C21 Iliac artery AT2-KO 10−07 to 10−4 M vasodilation in absence of AT1R 
blocker
15
C21 Coronary arteries wistar rat 10−04 to 10−3 M Initial inhibition of coronary flow 15
C21 Coronary arteries wistar rat 10−3 M Increase in coronary flow 15
C21 Coronary arteries SHR 10−05 to 10−3 M Initial inhibition of coronary flow 15
C21 Coronary arteries SHR 10−04 to 10−3 M Increase in coronary flow 15
C21 Coronary arteries Mouse (wild-type  
and AT2-KO)
10−10 to 10−3 M No effect 15
C21 Mesenteric  
arteries
SHR 10−10 to 10−5 M vasodilation in presence of AT1R 
blocker
32
Abbreviations: AT2R, angiotensin type 2 receptor; KO, knockout; SHR, spontaneously hypertensive rats; AT1R, angiotensin type 1 receptor.
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be speculated that the relative deficiency in AT2R during 
preeclampsia may contribute to the development of hyper-
tension. In a recent study, Hladunewich et al42 could, in fact, 
demonstrate that there is a strong correlation between AT1R/
AT2R ratio and the change in BP (the higher the ratio, the 
stronger the increase in BP; r=0.54) in women with previous 
severe preeclampsia who received a graded infusion of Ang 
II (1–3 ng/kg/min). The importance of the role of the AT2R 
for the development of preeclampsia still needs confirmation, 
but if it should turn out to really be of importance, AT2R 
agonists may be a treatment option of interest, although under 
“normal” conditions they do not lower BP.
Vascular remodeling
Chronically elevated BP causes an inflammatory response 
followed by excess synthesis and accumulation of extracel-
lular matrix mainly in the left cardiac ventricle, the kidneys, 
and the vascular wall. This fibrotic response to hypertension 
leads to deteriorated organ function and manifests as heart 
failure, renal disease, or vascular stiffening, the latter two 
of which reinforce the development of hypertension, thus 
establishing a vicious circle.43
Early studies on the role of AT2R stimulation on vascular 
remodeling could show that the beneficial effects of ARBs 
were, at least in part, due to indirect AT2R stimulation (use 
of ARBs leads to an increase in renin release and thus a rise 
in angiotensin II levels, which, in turn, stimulates the unop-
posed AT2Rs; ARB-induced Ang II levels are, however, 
much lower than pharmacological AT2 agonist levels), as 
these effects could be reversed by blockade of AT2Rs.44,45 
Further indirect evidence for a favorable role of AT2Rs 
in vascular remodeling is coming from studies in AT2R-
deficient mice, which responded with augmented vascular 
hypertrophy of coronary, aortic, and femoral arteries to 
chronically elevated BP.46–48
The impact of direct AT2R stimulation on hypertension-
induced vascular remodeling was studied recently in two 
studies in which C21 was applied orally to rats (Table 3).49,50 
Table 2 effects of new AT2R agonists on blood pressure
AT2 agonist Species/strain Dosage Result Reference
β-substituted  
Ang peptides
SHR 15 pmol/kg/min Iv MAP  only in presence of a low-dose  
AT1R blocker
8
C21 SHR 100/300 ng/kg/min Iv MAP  only in presence of a low-dose  
AT1R blocker; AT2-dependent
14
C21 SHR 1,000 ng/kg/min Iv MAP ; AT1R-dependent 14
C21 wistar–Kyoto rats 50–300 ng/kg/min Iv No effect 14
C21 Sprague Dawley rats 100–300 ng/kg/min Iv No effect 22
C21 Obese Zucker rats 1 µg/kg/min Iv No effect 23
C21 Sprague Dawley rats 0.5 µg/µl/h ICv MAP  by central mechanisms 24
C21 L-NAMe-induced hypertension 0.3 mg/kg Bw IP No effect 31
C21 SHR 1 mg/kg Bw PO Increase after 1 week; no effect  
in weeks 2–5
32
C21 2K1C hypertension 0.3 mg/kg Bw IP No effect 39
C21 SHR-SP 10 mg/kg/day extended release  
from 0.5% Na-carboxymethylcellulose
No effect 40
C21 wistar rats 0.03/0.3 mg/kg Bw IP No effect 59
C21 C57Bl-6 1/3/10 µg/kg Bw IP No effect 60
C21 Obese Zucker rats 300 µg/kg/day IP No effect 61
C21 KK-Ay mice 10 µg/kg Bw IP No effect 62
Abbreviations: 2K1C, two-kidney, one-clip rat model; AT2R, angiotensin type 2 receptor; Bw, body weight; ICv, intracerebroventricularly; IP, intraperitoneally; Iv, 
intravenously; L-NAMe, Nω-nitro-L-arginine methyl ester hydrochloride; PO, orally; SHR, spontaneously hypertensive rats; SP, stroke-prone; AT1R, angiotensin type 1 receptor; 
MAP, mean arterial pressure.
Table 3 effects of new AT2R agonists on vascular remodeling
AT2 agonist Species/model Dosage Result Reference
C21 L-NAMe-induced  
hypertension
0.3 mg/kg Bw IP Reduced aortic wall thickness and collagen content;  
lowered pulse wave velocity
31
C21 SHR 1 mg/kg Bw PO Reduced mesenteric artery stiffness; reduced aortic  
collagen and fibronectin content; lowered oxidative stress
32
Abbreviations: AT2R, angiotensin type 2 receptor; Bw, body weight; IP, intraperitoneally; L-NAMe, Nω-nitro-L-arginine methyl ester hydrochloride; PO, orally; SHR, 
spontaneously hypertensive rats.
Integrated Blood Pressure Control 2013:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
157
AT2-receptor function in vasculature and kidney
The authors of these studies used different models of 
hypertension: ie, stroke-prone spontaneously hypertensive 
rats (SHR-SP) in one study,50 and inhibition of endothelial 
nitric oxide synthase by application of Nω-nitro-L-arginine 
methyl ester hydrochloride (L-NAME) in the other study.49 In 
both studies, the effect of AT2R stimulation was compared 
with the effect of an ARB alone or the combination of both. 
The main finding of both studies was that treatment with an 
AT2R agonist widely prevented the development of vascu-
lar hypertrophy and fibrosis. Remarkably, this reversal of 
hypertension-induced pathology was achieved without any 
significant effect on BP: ie, although BP stayed elevated in 
C21-treated rats, vascular remodeling was almost completely 
prevented.49,50 The preventive effect of AT2R stimulation on 
vascular remodeling was shown in both studies to be related 
to a decrease in collagen deposition. Moreover, in our study 
in L-NAME-induced hypertension in rats, we measured 
pulse wave velocity, a marker for arterial stiffness and 
independent predictor of cardiovascular risk in patients, and 
we could again show that this indicator of vascular remod-
eling, which was increased in vehicle-treated hypertensive 
animals, was significantly attenuated in C21-treated, (still) 
hypertensive animals.49
BP in our study was not significantly changed by treat-
ment with C21, but there was a trend toward a reduction 
in BP, which may have been a result of reduced arterial 
stiffness.49
Kidney function
AT2-receptor deficiency in renal  
disease and injury
Considering the ubiquitous expression of the AT2R in fetal 
kidney, it may be surprising that AT2R knockout mice show 
no renal abnormalities in histology.24,51 However, obvious 
differences in disease progression in AT2R knockout mice 
when compared with wild-type mice were revealed in the 
renal ablation model of renal injury.51 Aggravated glomerular 
damage and impairment of renal function were shown in 
AT2R-deficient mice compared with wild-type mice, subse-
quently culminating in higher overall mortality.  Moreover, 
albuminuria in knockout mice was pronounced and renal 
macrophage infiltration of glomerulus and interstitium 
increased compared with wild-type mice. Benndorf et al51 
ruled out systolic BP differences, podocyte or basal mem-
brane damage, or upregulation of AT1Rs as possible causes 
for enhanced renal injury. Nonetheless, they elucidated one 
of the possible underlying mechanisms of disease progression 
in AT2R-deficient mice by showing a significant upregulation 
of asymmetric dimethylarginine, an endogenous inhibitor of 
nitric oxide synthase, in the knockout group, suggesting that 
the impairment in synthesis of nitric oxide may account for 
the aggravation of glomerular damage observed.
In accordance with these results, aggravated renal 
injury was observed in unilateral ureteral obstruction of 
AT2R-deficient mice, comprising severe interstitial fibrosis 
and greater abundance of fibroblasts and myofibroblasts in 
ipsilateral kidneys.52
Moreover, in a model of type 1 diabetes in mice, AT2R 
knockout animals exhibited accelerated development of 
diabetic nephropathy.53 Extracellular matrix (ECM) protein 
accumulation was measured by quantification of periodic 
acid–Schiff and Masson trichrome staining, as well as real-
time quantitative polymerase chain reaction analysis of 
renal collagen IV messenger ribonucleic acid expression. 
Terminal deoxynucleotidyl transferase dUTP nick end label-
ing assay was performed to semiquantify tubular apoptosis 
between groups. ECM accumulation and renal expression 
of collagen IV were significantly enhanced in nondiabetic 
AT2R knockout mice compared with nondiabetic controls. 
Additionally, tubular apoptosis was significantly increased 
in nondiabetic AT2R knockout mice. Accordingly, similar 
observations of increased ECM production and tubular 
apoptosis in AT2R-deficient animals were made in diabetic 
knockout animals when compared with wild-type mice, 
although values reached significance only for Masson 
trichrome staining arbitrary units. Chang et al53 proposed 
that an increase in Heme oxygenase 1 expression, observed 
in proximal tubule cells of AT2R knockout mice, enhances 
oxidative stress. Moreover, an elevated ACE/ACE2 ratio in 
knockout animals could account for aggravation of renal 
injury during diabetic nephropathy.
It is important to note that deterioration of renal injury 
in AT2R-deficient mice may result from a persistent but yet 
unnoticed impairment in renal function that evolved during 
fetal development, due to the absence of the AT2R, which 
is usually expressed in high density during fetal life, and 
may not represent missing counter-regulatory actions of the 
receptor itself in the adult organism.
AT2 receptor activation in renal 
physiology and disease
So far, studies investigating the role of the AT2R in renal 
disease were conducted under 1) AT1R blockade with subse-
quent Ang II administration, 2) using the peptide agonist CGP 
42112, or 3) under AT2R blockade achieved by administra-
tion of PD 123319. Findings in this regard have been recently 
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summarized and will not be further discussed in this review.54,55 
Interpretation of results, however, is confounded by possible 
antagonistic effects of CGP 42112 and by agonistic effects of 
PD 123319 on the AT1R or even the AT2R, depending on 
 timing and dosage.28,56 Since C21 became available for experi-
mental research, data about the role of the AT2R in kidney func-
tion have become more consistent and unequivocally strengthen 
the idea of a protective role of the AT2R in renal disease and 
of a natriuretic effect of AT2R stimulation (Table 4).
In Sprague Dawley rats, graded infusion of C21 (peak 
dosage: 300 ng/kg/min) significantly enhanced renal blood 
flow by simultaneously reducing renal vascular resistance 
in both female and male animals.35 In addition, urine flow, 
urinary sodium excretion, and fractional sodium excretion 
showed a significant increase when compared with vehicle-
treated groups. All effects observed were abolished by 
concomitant administration of PD 123319. Interestingly, 
glomerular filtration rate remained stable in the C21 group, 
albeit the presence of renal vasodilation suggesting that the 
C21-induced increase in natriuresis is altered due to an effect 
on tubular function, but not due to hemodynamic effects. All 
effects were BP independent, as there was no statistically 
significant difference in BP between vehicle- and C21-treated 
animals. However, there was a small but significant differ-
ence between the C21- and the C21 plus PD 123319-treated 
animals (BP in PD 123319-treated animals being lower), but 
from these data it cannot be decided whether this difference 
was due to an effect of C21 or of PD 123319 or of both.35
An AT2R-dependent but BP-independent natriuretic 
effect of C21 was further described recently in obese Zucker 
rats.36 In analogy to the study by Hillard et al,35 glomerular 
filtration rate remained unchanged in these animals, speaking 
again for a direct, tubular effect of C21.
In the two-kidney, one-clip rat model of hypertension 
(2K1C), Matavelli et al57 evaluated the effects of AT2R 
stimulation in early renal inflammation. In 2K1C rats, 
kidney perfusion is reduced by unilateral clipping of the 
renal artery. Inflammatory markers of the subsequently 
 developing ischemia were determined by in vivo recovery 
levels of renal intestinal fluid. Animals received vehicle, C21 
(0.3 mg/kg/day, intraperitoneally), PD 123319 (10 mg/kg/day, 
osmotic minipump), or C21 plus PD 123319 over the 4-day 
course of the study. Unilateral stricture of the renal artery led 
to a significant increase in AT2R protein expression, which 
was even further enhanced in the C21 group but abolished 
by administration of PD 123319. Expression of tumor necro-
sis factor (TNF)-α, transforming growth factor (TGF)-β1, 
and interleukin (IL)-6 messenger ribonucleic acid and their 
renal interstitial fluid (RIF) recovery rates were significantly 
elevated in 2K1C compared with sham-operated animals. In 
contrast, nitric oxide and cyclic guanosine monophosphate 
RIF recovery rates were significantly reduced. Treatment 
with C21 reduced TNFα, TGFβ1, and IL-6 expression and, 
moreover, increased RIF recovery rates for nitric oxide and 
cyclic guanosine monophosphate. Extensive inflammatory 
cell infiltration observed by histological (hematoxylin/eosin) 
staining of 2K1C renal cortex and medulla was significantly 
reduced with C21 treatment when compared with the vehicle 
group. These effects were only partially inhibited by the AT2R 
antagonist PD 123319.57
SHR-SPs represent an animal model of hypertension, 
characterized by the progressive development of renal 
damage and brain abnormality against the background of 
elevated Ang II blood levels. Oral treatment with C21 (peak 
dosage group: 10 mg/kg, suspended release from 0.5% 
sodium carboxymethylcellulose) significantly delayed the 
development of proteinuria and prevented the accumulation 
of high-molecular-weight proteins, which present markers 
of renal inflammation, in 24-hour urine electrophoresis.58 
Although plasma renin activity increased significantly in 
the vehicle group, plasma renin activity remained at basal 
levels in animals treated with C21. Finally, analysis of kidney 
histopathology revealed reduced renal lesions (attenuation 
of vascular lesions, tubular damage, luminal cast formation, 
glomerular sclerosis, inflammatory infiltrates) and attenu-
ated renal macrophage infiltration in rats treated with C21. 
Table 4 effects of new AT2R agonists on kidney function and pathology
AT2 agonist Species/strain Dosage Result Reference
C21 Sprague Dawley rats 100–300 ng/kg/min Iv Natriuresis, GFR unchanged 22
C21 Obese Zucker rats 5 µg/kg/min Iv Natriuresis, GFR unchanged 23
C21 2K1C hypertension 0.3 mg/kg Bw IP Attenuated renal inflammation 39
C21 SHR-SP 10 mg/kg/day in 0.5% carboxymethyl-cellulose Attenuation of albuminuria 40
C21 SHR-SP 10 mg/kg/day in 0.5% carboxymethyl-cellulose Attenuated renal fibrosis and inflammation 40
C21 Obese Zucker rats 300 µg/kg/day IP Attenuated renal inflammation 61
Abbreviations: 2K1C, two-kidney, one-clip rat model; AT2R, angiotensin type 2 receptor; BW, body weight; GFR, glomerular filtration rate; IP, intraperitoneally; IV, 
intravenously; SHR, spontaneously hypertensive rats; SP, stroke-prone.
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Furthermore neoexpression of vimentin, a marker of 
tubulointestinal injury, was completely prevented by AT2R 
stimulation with C21.58
Summary and conclusion
AT2R stimulation elicits effects on several physiological 
mechanisms, which contribute to the regulation of BP. 
 Specifically, AT2R agonists induce vasodilation in iso-
lated vessels ex vivo and they enhance natriuresis in vivo. 
 Furthermore, in hypertensive rats, AT2R stimulation attenu-
ates arterial stiffening. Nevertheless, in vivo BP is not altered 
acutely and only modestly chronically, the latter usually 
not reaching statistical significance. The lack of acute 
effect is probably due to some kind of counter-regulatory 
mechanism(s), which has not been characterized yet, but may 
involve activation of the “classic” RAS (increased levels of 
Ang II acting on the AT1R) or of the sympathetic nervous 
system. The trend toward a reduction in BP in more chronic 
settings seems likely due to secondary mechanisms such as 
natriuresis leading to volume reduction or attenuated vascular 
remodeling, resulting in lower peripheral resistance.
According to these reviewed data from preclinical animal 
or in vitro/ex vivo studies, it is likely that AT2R agonists 
will be unsuitable as antihypertensive monotherapeutics in 
clinical use. However, they may enhance the effectiveness of 
other, established antihypertensives, and they may provide 
additive benefit in respect of protection from hypertensive 
end-organ damage. However, these assumptions need to 
be verified in future clinical studies.
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